TransMedics Group, Inc. (NASDAQ:TMDX) has received a consensus “Moderate Buy” rating from brokerages, with an average 12-month price target of $144.25. Analysts have recently raised price targets, indicating bullish sentiment, while institutional investors hold nearly all of the stock. Insider selling occurred last quarter, totaling approximately $1.26 million.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
TransMedics Group, Inc. (NASDAQ:TMDX) has received a consensus “Moderate Buy” rating from brokerages, with an average 12-month price target of $144.25. Analysts have recently raised price targets, indicating bullish sentiment, while institutional investors hold nearly all of the stock. Insider selling occurred last quarter, totaling approximately $1.26 million.